BORTEZOMIB COMBINED WITH HISTONE DEACETYLASE INHIBITOR ITF2357 OR ARSENIC TRIOXIDE EXERTS SYNERGISTIC ANTI-PROLIF- ERATIVE AND PRO-APOPTOTIC EFFECTS IN P39 CELL LINE: A POSSI- BLE NEW APPROACH TO HIGH-RISK MYELODYSPLASTIC SYNDROMES